Yohimbe

Pausinystalia johimbe is a tall evergreen tree in the coffee family (Rubiaceae), native to coastal forests of Cameroon, Gabon, Equatorial Guinea, and neighboring West-Central Africa. Mature trees can exceed 30 meters, with a straight bole and bark that is gray-brown and relatively smooth when young, becoming more fissured with age. Leaves are opposite, glossy, elliptic to oblong, with prominent venation. Small flowers are borne in clusters; fruit is a capsule typical of the family.

The medicinal part is dried stem bark. Yohimbine is the headline alkaloid; related indoles (including rauwolscine in some analyses of related materials) may be present. Alkaloid content varies by tree, bark thickness, harvest, and storage. That variability is a safety problem: two products labeled “yohimbe bark” can differ several-fold in yohimbine.

Nomenclature is messy in commerce. Scientific names Pausinystalia johimbe and Corynanthe yohimbe appear on labels; “yohimbe” is also loosely applied to extracts standardized (or claimed to be standardized) to yohimbine. Prescription yohimbine HCl is a single salt with a milligram dose. Bark powder is a mixture.

Wild harvest and demand have raised conservation and adulteration concerns. Identity testing matters: stimulant blends sold for libido may contain undeclared pharmaceuticals or extra caffeine rather than authentic bark.

Yohimbe bark has a documented role in some West African traditional practices as a stimulant and aphrodisiac. German colonial-era pharmacy isolated yohimbine in the late nineteenth century and introduced it into European materia medica. Through the twentieth century, yohimbine hydrochloride was used as a prescription drug for erectile dysfunction before PDE5 inhibitors (sildenafil and relatives) largely displaced it in ordinary urology practice.

The supplement market kept the folklore. Capsules, “stacks,” and energy-sexuality blends sold yohimbe as a natural alternative—often without the dose control of the prescription salt. FDA and other regulators have warned that yohimbe products can be mislabeled, over-potent, or contaminated, and that serious adverse events (including heart attack, seizure, and severe hypertension) have been reported.

NCCIH and MedlinePlus summaries treat yohimbe as a bark with a plausible mechanism and a poor safety margin in unsupervised use. The historical arc is from traditional bark to a characterized alkaloid to a chaotic consumer product—the last of those is what most people actually buy.

Conservation status and CITES-adjacent concern for overharvested African medicinal trees sit in the background: demand for bark is not only a clinical issue.

Yohimbine is a selective alpha-2 adrenergic antagonist. Blocking presynaptic alpha-2 receptors increases norepinephrine release. Peripherally that can affect vascular tone and, in some men, erectile physiology; centrally it can increase arousal, anxiety, tremor, and blood pressure. The same pathway explains both the advertised effect and the panic-attack, tachycardia, and hypertensive crisis reports.

The drug is metabolized in part by CYP2D6; poor metabolizers and drug interactions can raise exposure. Half-life of the pharmaceutical salt is on the order of hours, not a gentle all-day tea. Bark adds unknown extra alkaloids and a poorly quantified yohimbine dose.

Yohimbine is not a PDE5 inhibitor. Combining it with sildenafil-class drugs or nitrates is an uncontrolled cardiovascular experiment. It is also not a testosterone replacement.

Because bark products are inconsistently standardized, “following the label” does not guarantee a pharmaceutical-grade milligram amount. That is the core quality failure of the category.

The traditional and commercial claim is male sexual function: erectile difficulty, libido, and athletic “fat-burning” stacks. Prescription yohimbine HCl has randomized-trial evidence for some men with erectile dysfunction, with a modest effect size and a meaningful adverse-event rate. That evidence does not automatically transfer to grocery-store bark capsules.

Weight-loss and bodybuilding marketing cites yohimbine’s effect on lipolysis in experimental settings. Human evidence for meaningful, safe fat loss from yohimbe supplements is weak, and the cardiovascular cost is not theoretical.

Yohimbe is sometimes promoted for orthostatic hypotension or as an antidepressant adjunct. Those are clinician-supervised drug questions, not DIY bark tea indications.

It is not a treatment for infertility, prostate disease, or relationship problems. Chest pain, sudden severe headache, or an erection lasting hours needs emergency care—not a second capsule.

Commerce offers crude dried bark, powdered bark capsules, liquid extracts, and products labeled as yohimbine or “standardized yohimbe.” Pharmaceutical yohimbine hydrochloride is a prescription medicine in some jurisdictions and is not the same SKU as a supplement.

There is no reliable kitchen dose of bark. Traditional decoctions exist in ethnography; they are not a protocol to copy at home. If a clinician uses yohimbine HCl, the milligram amount is specified and monitored.

Multi-ingredient “male enhancement” and pre-workout blends may hide yohimbe or yohimbine among caffeine, synephrine, and other stimulants. Read full labels. More bottles is how hypertensive emergencies happen.

Do not chew unidentified African barks. Species identity, alkaloid load, and adulteration all matter.

Common effects of yohimbine include anxiety, insomnia, headache, nausea, sweating, tremor, palpitations, and raised blood pressure. Flushing and dizziness are also reported. These can appear at doses people consider “just one capsule.”

Serious events include hypertensive crisis, arrhythmia, myocardial infarction, seizure, and acute psychiatric decompensation (panic, mania, psychosis in vulnerable people). Overdose and high-potency mislabeled products are recurring themes in poison-center and FDA case series.

Priapism is uncommon but is a urologic emergency. Gastrointestinal upset is milder but common.

MedlinePlus and NCCIH emphasize that the safety profile of unsupervised bark is worse than marketing implies. “Natural” does not mean a wide therapeutic index.

Do not use yohimbe or yohimbine if you have uncontrolled hypertension, heart disease, arrhythmia, stroke history, seizure disorder, severe anxiety or panic disorder, bipolar mania, or significant kidney or liver disease—unless a specialist who knows the drug is directing a pharmaceutical product.

Pregnancy and breastfeeding are inappropriate settings for yohimbe. Children and adolescents should not take it. Prostate surgery or urologic conditions that make priapism more dangerous are additional reasons to avoid unsupervised use.

People taking MAOIs, many antidepressants, stimulants, or blood-pressure medicines should treat yohimbe as off-limits without explicit clinical approval. Allergy to the plant is a stop.

Anyone told never to take OTC decongestants or “pre-workout” stimulants because of blood pressure should treat yohimbe the same way.

The dangerous combinations are pharmacologic, not folklore. MAO inhibitors plus yohimbine can produce severe hypertension. Other antidepressants (including some SSRIs and SNRIs in case reports) and stimulants (amphetamine, high-dose caffeine, ephedrine-like agents) can compound tachycardia and blood pressure.

Nitrates, PDE5 inhibitors, and alpha-blockers used for prostate or blood pressure create unpredictable vascular effects when mixed with an alpha-2 antagonist. Do not invent a bedroom cocktail.

CYP2D6 inhibitors may raise yohimbine levels. Clonidine and other alpha-2 agonists can be antagonized—the opposite of what those drugs are for.

Tell clinicians and pharmacists about any yohimbe product before anesthesia, new psychiatric medicines, or cardiovascular procedures. Hide-the-supplement is how interactions get missed.